All relevant data are available in the paper.

Introduction {#sec005}
============

One million children die each year in low- and middle-income countries in the first 4 weeks of life because of neonatal sepsis \[[@pone.0148052.ref001]\]. Early-onset neonatal sepsis (EOS), occurring in the first week of life, accounts for approximately 80% of cases, and is caused by bacteria that are transmitted vertically from the genital tract of the mother to infant before or during delivery \[[@pone.0148052.ref002]\]. Late-onset neonatal sepsis (LOS) occurs between week 1 and month 2 to 3 of life and may be caused by bacteria acquired vertically or horizontally \[[@pone.0148052.ref003]\]. Because the transfer of a single species from the maternal genitourinary tract to the neonate before or during delivery is a prerequisite for EOS \[[@pone.0148052.ref004]\], there are unique opportunities for prevention of EOS.

At present, *Streptococcus agalactiae* (Group B *Streptococcus*, GBS) and *Escherichia coli* are the leading causes of EOS worldwide \[[@pone.0148052.ref005]\]. Furthermore, GBS and *E*. *coli* are associated with preterm birth, very-low-birth-weight delivery and puerperal sepsis \[[@pone.0148052.ref006], [@pone.0148052.ref007]\], which cause substantial morbidity and mortality in sub-Saharan Africa (SSA) \[[@pone.0148052.ref002], [@pone.0148052.ref008], [@pone.0148052.ref009]\].

To prevent EOS, efforts have been focusing mainly on GBS and high-income countries, based on two strategies, namely the screening- or risk-based administration of intrapartum antibiotic prophylaxis (IAP) and the development of vaccines \[[@pone.0148052.ref010]\].

IAP has been shown to reduce the incidence of GBS EOS from 1.7/1000 to 0.6/1000 in the US \[[@pone.0148052.ref011]\], but is not effective against *E*. *coli* EOS, LOS, and adverse perinatal outcomes related to GBS \[[@pone.0148052.ref012], [@pone.0148052.ref013]\]. Furthermore, according to the current universal guidelines (Centers for Disease Control and Prevention, CDC), IAP should be administered to women found positive for GBS at 35--37 weeks of gestation \[[@pone.0148052.ref014]\]. However, these guidelines are not followed in most health-care facilities in low-income countries. The use of intravaginal washes with chlorhexidine (a wide-spectrum microbicide) during labour and neonatal wipes with chlorhexidine, has been explored in low- and middle-income countries, but is unlikely to prevent vertically acquired neonatal infections in any setting or population \[[@pone.0148052.ref004]\].

Most GBS vaccines under development aim at eliciting protective antibodies against capsular polysaccharides (CPS), the most important GBS virulence factor of which ten antigenically distinct CPS are known \[[@pone.0148052.ref010]\], and are attractive as some of the IAP-related problems may be circumvented \[[@pone.0148052.ref010]\]. However, these vaccines might not be effective in low-income countries because of different serotype distribution \[[@pone.0148052.ref015]\].

Although SSA has the highest rates of neonatal sepsis mortality worldwide, epidemiological data on vaginal GBS and *E*. *coli* carriage are very limited but necessary to develop and implement prevention strategies \[[@pone.0148052.ref016], [@pone.0148052.ref017]\]. Therefore, in this multi-country cross-sectional study, we assessed the vaginal GBS and *E*. *coli* carriage prevalence, risk factors for GBS and *E*. *coli* carriage, and GBS serotype distribution in populations from three countries: Kenya, Rwanda and South Africa.

Patients and Methods {#sec006}
====================

Study design and population {#sec007}
---------------------------

In 2010--2011, we conducted a multi-country follow-up study entitled ''Characterisation of novel microbicide safety biomarkers in East and South Africa". The main aim of that project was to characterise the vaginal microbiome and the cervicovaginal mucosal immune system in African women and to assess changes of these over time \[[@pone.0148052.ref018]--[@pone.0148052.ref021]\]. In that study, 430 women were recruited at three study sites, i.e. the International Centre for Reproductive Health Kenya (ICRHK) in Mombasa, Kenya (170 women); the non-governmental organisation Rinda Ubuzima (RU) in Kigali, Rwanda (60 women), and the Wits Reproductive Health and HIV Institute (Wits RHI) in Johannesburg, South Africa (SA) (200 women). The women were recruited into 6 predefined study groups: a reference group of 219 women (adult, non-pregnant, HIV-negative women at average risk of HIV), 60 pregnant women (up to 14 weeks of gestational age as determined by abdominal ultrasound at recruitment), 60 adolescent girls (16--17 years), 31 HIV-negative women engaging in vaginal practices (usage of cloth, lemon juice, or detergents to clean, dry or tighten the vagina on a regular basis), 30 self-acknowledged female sex workers (FSW), and 30 HIV-positive women (on antiretroviral treatment for at least 6 months, asymptomatic and with a CD4 count of more than 350 cells/μl) ([Table 1](#pone.0148052.t001){ref-type="table"}). Participants were eligible for inclusion if they were in good physical and mental health, able and willing to participate in the study as required by the protocol, able and willing to give written informed consent (including written parental or guardian consent for adolescents). Women were excluded if they had never had penetrative vaginal intercourse, if they had a history of hysterectomy or other genital tract surgery in the three months prior to the screening visit, if external and/or internal genital warts were found, if they were enrolled in HIV prevention trials involving investigational products, if they were less than 6 months post-partum at the time of enrolment, if they were HIV-positive (unless for inclusion in the HIV-positive women group), or if they were pregnant (unless for inclusion in the pregnant women group). The study population, followed up for approximately eight months per person over 8 visits, is described in detail by Jespers and coworkers \[[@pone.0148052.ref019]\].

10.1371/journal.pone.0148052.t001

###### Study population and vaginal GBS and *E*. *coli* carriage rates.

![](pone.0148052.t001){#pone.0148052.t001g}

  City, Country          Group               n     GBS prevalence % (95% CI)   *E*. *coli* prevalence % (95% CI)
  ---------------------- ------------------- ----- --------------------------- -----------------------------------
  **Mombasa, Kenya**     Reference group     110   20.2 (13.7--28.7)           25.0 (17.8--33.9)
  **Mombasa, Kenya**     Pregnant women      30    14.3 (5.7--31.5)            14.3 (5.7--31.5)
  **Mombasa, Kenya**     Adolescents         30    3.6 (0.6--17.7)             28.6 (15.3--47.1)
  **Kigali, Rwanda**     FSW                 30    20.0 (9.5--37.3)            70.0 (52.1--83.3)
  **Kigali, Rwanda**     HIV+ women          30    0.0 (0.0--11.4)             20.0 (9.5--37.3)
  **Johannesburg, SA**   Reference group     109   23.2 (16.2--31.9)           27.1 (19.6--36.2)
  **Johannesburg, SA**   Pregnant women      30    10.0 (3.5--25.6)            33.3 (19.2--51.2)
  **Johannesburg, SA**   Adolescents         30    0.0 (0.0--11.4)             13.3 (5.3--29.7)
  **Johannesburg, SA**   Vaginal practices   31    25.8 (13.7--43.2)           30.0 (16.7--47.9)

The current study presents one of the tertiary objectives of the above mentioned study, namely to document the vaginal carriage rates of the main pathogens associated with EOS (GBS and *E*. *coli*) and the risk factors for their carriage. These analyses are based on the screening visit and the first visit (scheduled soon after the last day (day 9 +/- 2 days) of the menstrual period) from the follow-up study.

Study procedures {#sec008}
----------------

At the screening visit, blood, vaginal, endocervical and urine samples were taken for diagnostic testing of HIV, HSV-2, syphilis, *Neisseria gonorrheae* (NG), *Chlamydia trachomatis* (CT), *Trichomonas vaginalis* (TV), urinary tract infection (UTI), pregnancy, cervical dysplasia (by Pap smear), bacterial vaginosis (BV) (Amsel criteria), and vaginal candidiasis. Treatment was provided according to national guidelines, voluntary HIV counseling was offered, and condoms were provided free-of-charge.

At visit 1, two sterile Copan flocked^®^ vaginal swabs (Copan Diagnostics, Inc., Murrieta, CA), to be used for the molecular detection of GBS and *E*. *coli*, were brought into the vaginal vault by the study clinician, rotated against the vaginal wall at the midportion of the vault, gently dipped in the posterior fornix and carefully removed to prevent contamination with the microbiome of the vulva and introitus. The swab heads were collected into two 1.5 ml cryovials, labelled and immediately frozen at -80°C until shipment to the central laboratory at the Institute of Tropical Medicine (ITM, Antwerp, Belgium) using temperature-monitored dry shippers filled with liquid nitrogen. One Amies swab (Copan Diagnostics, Inc.) for culturing was taken in a likewise manner, placed in the Amies tube, and transported at 4°C in a temperature-monitored cooler to the local laboratory, where it was processed immediately. At both visits, women were interviewed during face-to-face interviews about their general and sexual health, vaginal habits and sociodemographic characteristics. A physical examination including speculum and bimanual pelvic examination was carried out by a clinician. At each visit, participants were compensated for their time and transportation.

Diagnosis of genital infections {#sec009}
-------------------------------

At the local laboratories, tests for HIV, HSV-2, syphilis, CT and NG were performed. For immediate detection of *Candida* cells and hyphae, TV, and clue cells, wet mount microscopy was used. For the purpose of this study, a commercially available TV InPouch^TM^ system (BioMed Diagnostics, White City, Oregon) was used. For this, a vaginal swab was inoculated according to the manufacturer's instructions and InPouch cultures were monitored on a daily basis. InPouch bags with no growth at the end of five days were considered negative. BV diagnosed according to the Amsel criteria was used for immediate treatment. For research, vaginal smears were made and sent to ITM for Gram staining and Nugent scoring, a scoring system to diagnose BV. Briefly, smears from vaginal swabs were prepared by rolling the swab onto a glass slide. Slides were air-dried and fixed using 70% ethanol. For the Gram-staining at ITM, the fixed smear was covered with crystal violet for 1 minute, washed with water, flooded with Lugol's iodine for 1 minute, washed with water, and then decolorized with acetone-alcohol for 2--3 seconds. The smears were rinsed quickly under running water to stop the decolorisation and then counterstained with safranin for 1 minute. All reagents were from Becton Dickinson (BD). All smears were examined microscopically with the 40X objective to check the staining and the distribution of the material, and then assessed under oil immersion objective (1000x magnification) using the grading system described by Nugent and co-workers \[[@pone.0148052.ref022]\]. The Nugent score is calculated by assessing for the presence of *Lactobacillus* cell types, small Gram-variable coccobacilli, and curved Gram-variable rods. A score of 0--3 is considered as normal (BV-negative); a score of 4--6 as an intermediate vaginal microbiome; and a score of 7--10 as BV-positive.

DNA extraction {#sec010}
--------------

For the molecular detection of GBS and *E*. *coli*, DNA extraction from the two Copan swabs of each subject was carried out at ITM by thawing the swabs at room temperature for 30 minutes. After adding 1200 μL of diluted PBS, each swab was gently vortexed for 15 seconds, and 1 mL of each swab suspension was pooled into a final volume of 2 mL. An aliquot of 250 μL was extracted using the Abbott m24sp automated extraction platform (Abbott, Maidenhead, UK), according to the manufacturer's instructions, and 200 μl of eluted DNA---to be used in the quantitative PCR (qPCR) assays---was stored at-- 80°C.

For the construction of qPCR standard curves, DNA was extracted from overnight cultures of *S*. *agalactiae* LMG 14694^T^ on TSA + 5% sheep blood, *E*. *coli* ATCC 25922 grown on TSA + 5% sheep blood, and *C*. *albicans* ATCC 90028 grown on Sabouraud agar (all BD). All growth was harvested from the plate and resuspended in 1 ml of saline. DNA of this suspension was extracted using the High Pure PCR Template Preparation Kit (Roche Applied Science, Basel, Switzerland) according to the manufacturer's instructions.

For capsular genotyping of GBS, 1 ml of inoculated Lim Broth medium (see [Microbiological culturing](#sec014){ref-type="sec"}) was used for DNA extraction using the High Pure PCR Template Preparation Kit (Roche), according to the the manufacturer's instructions.

*Streptococcus agalactiae* qPCR {#sec011}
-------------------------------

To detect *S*. *agalactiae* in vaginal DNA extracts, a *S*. *agalactiae* specific qPCR was carried out, using primers previously described \[[@pone.0148052.ref023]\]. The qPCR reactions for *S*. *agalactiae* were performed in a final volume of 10 μl, containing 5 μl of LightCycler 480® SYBR Green I Master (Roche), 0.5 μM of both forward primer Sip1 (5'-ATCCTGAGACAACACTGACA-3') and reverse primer Sip2 (5'-TTGCTGGTGTTTCTATTTTCA-3'), 0.3 μM of probe (5'- 6-FAM--ATCAGAAGAGTCATACTGCCACTTC--TAMRA-3') (Eurogentec, Liège, Belgium) and 2 μl of DNA extract or 2 μl of HPLC water (as negative template control). Cycling conditions were as follows: 95°C for 5 min; 40 cycles of 95°C for 10 s, 58°C for 15 s and 72°C for 20 s. For the standard series, DNA concentration of the extract of *S*. *agalactiae* LMG 14694^T^ was determined using the Qubit® Fluorometer (Invitrogen, Auckland, New Zealand) and the genomic concentration was calculated based on the GC% content and genome size of the type strain. A tenfold dilution standard series of *S*. *agalactiae* LMG 14694^T^ DNA was prepared by dilution of the DNA stock in HPLC grade water. All standard tenfold dilution series and samples were run in duplicate. Amplification, detection and quantification were carried out using the LightCycler480® platform and the LightCycler® 480 Software Version 1.5 (Roche).

*Escherichia coli* qPCR {#sec012}
-----------------------

To detect *E*. *coli* in vaginal DNA extracts, an *E*. *coli* specific qPCR was carried out, using primers targeting the β-glucuronidase encoding gene uidA, previously described \[[@pone.0148052.ref024]\]. The qPCR reactions were performed in a final volume of 10 μl, containing 5 μl of LightCycler 480® SYBR Green I Master (Roche), 0.3 μM of both forward primer EcoliFW (5'-CAACGAACTGAACTGGCAGA-3') and reverse primer EcoliRV (5'- CATTACGCTGCGATGGAT -3') (Eurogentec) and 2 μl of DNA extract or 2 μl of HPLC water (as negative template control). Cycling conditions were as follows: 50°C for 2 min, 95°C for 10 min; 40 cycles of 95°C for 15 s and 60°C for 1 min. A standard series (using *E*. *coli* ATCC 25922 grown on TSA + 5% sheep blood (BD)), was constructed as described for *S*. *agalactiae*.

*Candida albicans* qPCR {#sec013}
-----------------------

To detect *C*. *albicans* in vaginal DNA extracts, a *C*. *albicans* specific qPCR was carried out, using primers targeting the ITS-1 gene (adapted from \[[@pone.0148052.ref025]\]). The qPCR reactions were performed in a final volume of 10 μl, containing 5 μl of LightCycler 480® SYBR Green I Master (Roche), 0.3 μM of both forward primer CA_FW (5'-CAACGAACTGAACTGGCAGA-3') and reverse primer CA_RV (5'- CATTACGCTGCGATGGAT -3') (Eurogentec) and 2 μl of DNA extract or 2 μl of HPLC water (as negative template control). Cycling conditions were as follows: 50°C for 2 min, 95°C for 10 min; 40 cycles of 95°C for 15 s and 60°C for 1 min. A standard series (using *C*. *albicans* ATCC 90028 grown on Sabouraud agar (BD)), was constructed as described for *S*. *agalactiae*.

### Microbiological culturing {#sec014}

At the local laboratories, the Amies swab was inoculated on in-house TMB^plus^ plates (a medium supporting growth of anaerobes and allowing assessment of hydrogen peroxide production of strains) \[[@pone.0148052.ref026]\], after which the plates were incubated anaerobically as described previously \[[@pone.0148052.ref027]\]. After 48--72 h, depending on the growth, all biological material of the culture plate was harvested using sterile cotton swabs and stored in cryovials with 1 ml of tryptic soy broth + 5% glycerol at-- 80°C until shipment. After shipment to the ITM, bacteria from the cryovial were inoculated in commercial Lim Broth medium (BD)--a selective enrichment medium for GBS--according to the manufacturer's instructions (5% CO~2~ at 35°C for 24 hours). The latter procedure was performed only for women found to be positive for vaginal GBS carriage by means of qPCR. DNA extracts of inoculated Lim Broth medium was used for direct molecular capsular typing of GBS.

*S*. *agalactiae* molecular capsular typing {#sec015}
-------------------------------------------

To determine the GBS serotype, we used a flowchart described by \[[@pone.0148052.ref028]\], based on the multiplex PCRs with primers as described by Poyart and co-workers and Imperi and co-workers \[[@pone.0148052.ref029], [@pone.0148052.ref030]\]. The multiplex PCRs were performed directly on DNA extracted from the inoculated Lim Broth medium. The reactions were performed in a final reaction mixture of 20 μl, containing 10 μl of FastStart PCR Master Mix (Roche), 0.2 μM of each primer, and 2 μl of DNA template. Using a Veriti 96-well thermal cycler (Applied Biosystems, Foster City, CA), the following PCR program was run: 94°C for 5 min, 3 cycles of 45 s at 94°C, 2 min at 50°C, 1 min at 72°C, and 30 cycles of 20 s at 94°C, 1 min at 50°C and 1 min at 72°C, with a final extension at 72°C for 7 min. PCR amplification products were visualised under UV light after electrophoresis on 1% agarose gels (30 minutes at 10 V/cm) and staining with ethidiumbromide. Twenty five control strains (covering all GBS serotypes and provided by the Belgian *Streptococcus agalactiae* reference center (Dr. Pierette Melin, University of Liège, Belgium)) were used as a positive control.

Physiological parameters {#sec016}
------------------------

Vaginal pH was measured during the speculum examination by pressing commercial pH strips (pH Fix 3.6--6.1, Machery-Nagel) against the vaginal wall.

Detection of prostate-specific antigen (PSA), a marker for sexual intercourse within the past 24 hours \[[@pone.0148052.ref031]\] in vaginal swab fluid was performed using a chromatographic immune assay (the Seratec® PSA SemiQuant Cassette Test, Seratec, Gottingen, Germany) according to the manufacturer's instructions. Pregnancy was assessed by testing urine with a rapid hCG test (QuickVue One-Step hCG Test (Kigali, Johannesburg) or Unimed First Sign hCG test (Mombasa)). Leucocytes and erythrocytes in urine were detected using dipsticks according to the manufacturer's instructions (Siemens Multistix 10 sg in Kigali, Mission® urinalysis strips in Mombasa, and Neotest 4 Urine Dipstick in Johannesburg).

Statistical analysis {#sec017}
--------------------

Data were analyzed with SPSS software version 22 (SPSS Inc.). Prevalences were reported with their 95% confidence interval. Outcomes for this analysis were vaginal GBS carriage and vaginal *E*. *coli* carriage, as determined by a positive qPCR.

Independent variables considered were study site, sociodemographic characteristics, reproductive health characteristics, sexual behavioural factors, vaginal practices characteristics, cervicovaginal signs and symptoms and microbiological characteristics. Variables were analyzed using logistic regression in univariable and multivariable ways, with p-values \< 0.05 indicating significance. In order not to overfit our multivariable models, variables were restricted in proportion to the number of cases positive for GBS and *E*. *coli*, i.e. maximum one degree of freedom per 10 cases \[[@pone.0148052.ref032]\]. Variables included in the models were selected as follows \[[@pone.0148052.ref033]\]: firstly, only variables found to be significantly associated with GBS or *E*. *coli* carriage in univariable analysis were considered for inclusion the multivariate GBS or *E*. *coli* model, respectively. Subsequently, of correlated variables (e.g. 'having had recent vaginal intercourse' and a positive PSA test), only one was kept for further consideration to avoid collinearity. The final selection of variables was based on literature and clinical expertise/relevance. The multivariable models were controlled for possible confounding variables and were validated with bootstrap analysis.

Ethics statement {#sec018}
----------------

Written information and consent forms in the local language were provided to the women or to the Legally Authorized Representatives for their review. After the interview, the participants were asked to express their willingness to participate in the study by signing (or thumb-printing in case they were illiterate) the consent form. In case they were of minor age (age below 18 in Kenya and SA, and below 21 in Rwanda), also the parents or guardians were asked to give consent. The study was approved by the Kenyatta National Hospital Ethical Review Committee, Kenya; the Human Research Ethics Committee (Medical), University of the Witwatersrand, SA; the Rwanda National Ethics Committee, Rwanda; the Institutional Review Boards of the Institute of Tropical Medicine in Antwerp, of Ghent University, and of the University Teaching Hospital in Antwerp, Belgium. In addition, the study was approved by the National Council on Science and Technology in Kenya, and the National AIDS Control Commission in Rwanda. The study is registered at the Trial Registration at the National Health Research Ethics Council South Africa (DOH2709103223) \[[@pone.0148052.ref019]\].

Results {#sec019}
=======

Vaginal GBS and *E*. *coli* carriage and GBS serotype distribution {#sec020}
------------------------------------------------------------------

Of the 430 women enrolled in the study, 424 and 421 vaginal swab DNA extracts were analysed for the presence of GBS and *E*. *coli*, respectively. The vaginal GBS and *E*. *coli* carriage rates in the different study groups are presented in [Table 1](#pone.0148052.t001){ref-type="table"}.

The GBS serotype distribution is presented in [Table 2](#pone.0148052.t002){ref-type="table"} and [Fig 1](#pone.0148052.g001){ref-type="fig"}. For 12 GBS carriers, the serotype could not be determined because samples were no longer available. Serotype distribution was largely comparable between sites. The most prevalent serotypes were Ia (27.3%), V (27.3%), and III (22.7%) in Kenya; Ia (34.5%), V (31.0%), and IV (13.8%) in SA; and Ia (83.3%) and II (16.7%) in Rwanda.

![Distribution of GBS capsular serotypes.\
Left, Kenya (n = 22); middle, Rwanda (n = 6); right, South Africa (n = 29).](pone.0148052.g001){#pone.0148052.g001}

10.1371/journal.pone.0148052.t002

###### Studies reporting GBS serotype distribution of (recto)vaginal isolates in SSA.

![](pone.0148052.t002){#pone.0148052.t002g}

  Country      Year       Population      Ia           Ib         II         III          IV         V            VI         VII       VIII      IX         NT                                                                  Reference
  ------------ ---------- --------------- ------------ ---------- ---------- ------------ ---------- ------------ ---------- --------- --------- ---------- ------------------------------------------------------------------- ------------------------------------------------------------------
  The Gambia   1994       P               19           28         6          3            38                                                                \[[@pone.0148052.ref034]\][^\$^](#t002fn002){ref-type="table-fn"}   
  Malawi       2011       P, HIV+, HIV-   18.2         6.2        10.3       39.0         0.3        23.9         0.8                  0.8                  1.5                                                                 \[[@pone.0148052.ref035]\]
  SA           2011       P               30.1         6.7        11.3       37.3         3.7        10.2                                                                                                                       \[[@pone.0148052.ref036]\]
  SA           2014       P               36.2--41.4   3.5--4.6   7.2--7.5   31.3--34.9   2.0--4.0   10.3--15.6                                  0.0--3.3                                                                       \[[@pone.0148052.ref037]\]
  **Kenya**    **2015**   **P, NP**       **27.3**                           **22.7**                **27.3**     **13.6**   **4.5**   **4.5**                                                                                  **This study**
  **Rwanda**   **2015**   **NP**          **83.3**                **16.7**                                                                                                                                                      **This study**
  **SA**       **2015**   **P, NP**       **34.5**                           **10.3**     **13.8**   **31.0**                **6.9**   **3.4**                                                                                  **This study**
  Europe       2010       N/A             18.2         12.4       14.4       28.1         3.7        14.9         0.6        0.6       0.6                                                                                      \[[@pone.0148052.ref038]\][^£^](#t002fn003){ref-type="table-fn"}
  US           2010       N/A             26.8         8.1        10.9       24.8         1.0        15.0         0.3        0.0       0.2                                                                                      \[[@pone.0148052.ref038]\][^£^](#t002fn003){ref-type="table-fn"}

P, pregnant; NP, non-pregnant

^\$^determined serotypes I-VI (no differentiation between Ia and Ib); N/A, not applicable (review)

^£^data from meta-analysis but excluding isolates from non-sterile sites and from neonates were excluded.

Univariable and multivariable analyses {#sec021}
--------------------------------------

Tables [3](#pone.0148052.t003){ref-type="table"} and [4](#pone.0148052.t004){ref-type="table"} present the univariable associations of the sociodemographics, sexual behavior, vaginal practices, cervicovaginal signs and symptoms, and microbiological characteristics with vaginal GBS and *E*. *coli* carriage, respectively. Because of the low prevalence, CT, NG, TV, and syphilis were not considered for further analysis.

10.1371/journal.pone.0148052.t003

###### Sociodemographic characteristics, reproductive health, sexual behavior, vaginal practices, vaginal signs & symptoms, and microbiological associations with vaginal GBS carriage (univariable analysis).

![](pone.0148052.t003){#pone.0148052.t003g}

                                                                                                                                                              n     GBS+ n (%)   Crude OR (95% CI)    p-value[\*](#t003fn001){ref-type="table-fn"}
  ----------------------------------------------------------------------------------------------------------------------------------------------------------- ----- ------------ -------------------- ----------------------------------------------
                                                                                                                                                              424   69 (16.3)                         
  **Sociodemographic characteristics**                                                                                                                                                                
  **City (Country)**                                                                                                                                                                                  
  Mombasa (Kenya)                                                                                                                                             165   27 (16.4)    0.89 (0.51--1.53)    0.665
  Kigali (Rwanda)                                                                                                                                             60    6 (10.0)     0.50 (0.20--1.26)    0.142
  Johannesburg (SA)                                                                                                                                           199   36 (18.1)    1                    \-
  **Age (years)**                                                                                                                                                                                     
  \<18                                                                                                                                                        58    1 (1.7)      0.07 (0.01--0.50)    **0.008**
  18--24                                                                                                                                                      148   23 (15.5)    0.71 (0.41--1.23)    0.219
  \>24                                                                                                                                                        218   45 (20.6)    1                    \-
  **Educational level**                                                                                                                                                                               
  Higher educational level[^£^](#t003fn002){ref-type="table-fn"}                                                                                              189   39 (20.6)    1                    \-
  Lower educational level[^££^](#t003fn003){ref-type="table-fn"}                                                                                              235   30 (12.8)    0.56 (0.33--0.95)    **0.030**
  **Marital status**                                                                                                                                                                                  
  Never married                                                                                                                                               242   34 (14.0)    1                    \-
  Married                                                                                                                                                     148   30 (20.2)    1.55 (0.91--2.67)    0.109
  Separated/divorced/widowed                                                                                                                                  34    5 (14.7)     1.06 (0.38--2.91)    0.918
  **Socio-economic status**[^**\#**^](#t003fn004){ref-type="table-fn"}                                                                                                                                
  Low                                                                                                                                                         106   17 (13.0)    1                    \-
  Medium                                                                                                                                                      163   31 (19.0)    1.23 (0.64--2.36)    0.533
  High                                                                                                                                                        155   21 (13.5)    0.82 (0.41--1.64)    0.576
  **Reproductive health**                                                                                                                                                                             
  **Pregnant**                                                                                                                                                                                        
  No                                                                                                                                                          366   62 (16.9)    1                    \-
  Yes                                                                                                                                                         58    7 (12.1)     0.67 (0.29--1.55)    0.353
  **Parity**                                                                                                                                                                                          
  0                                                                                                                                                           149   18 (12.1)    1                    \-
  1--2                                                                                                                                                        211   42 (19.9)    1.81 (1.00--3.29)    0.052
  \>2                                                                                                                                                         64    9 (14.1)     1.19 (0.50--2.81)    0.690
  **Gravity**                                                                                                                                                                                         
  0                                                                                                                                                           118   14 (11.9)    1                    \-
  1--2                                                                                                                                                        210   38 (18.1)    1.64 (0.85--3.17)    0.141
  \>2                                                                                                                                                         96    17 (17.7)    1.60 (0.74--3.44)    0.230
  **Regular cycle**                                                                                                                                                                                   
  Yes                                                                                                                                                         256   42 (16.4)    1                    \-
  No/unknown                                                                                                                                                  168   27 (16.1)    0.98 (0.58--1.66)    0.927
  **Menstrual cycle**                                                                                                                                                                                 
  No cycle                                                                                                                                                    194   33 (17.0)    1                    \-
  With cycle                                                                                                                                                  230   36 (15.7)    0.91 (0.54--1.51)    0.706
  **Contraceptive**                                                                                                                                                                                   
  None                                                                                                                                                        73    15 (20.5)    1                    \-
  Condom only                                                                                                                                                 108   10 (9.3)     0.40 (0.17--0.94)    **0.035**
  Others (hormones/IUD/sterilisation/pregnant)                                                                                                                243   44 (18.1)    0.86 (0.44--1.65)    0.639
  **Currently breastfeeding**                                                                                                                                                                         
  No                                                                                                                                                          390   64 (16.4)    1                    \-
  Yes                                                                                                                                                         34    5 (14.7)     0.88 (0.33--2.36)    0.796
  **Sexual behaviour**                                                                                                                                                                                
  **Age at first sexual encounter (years)**                                                                                                                                                           
  \<16                                                                                                                                                        80    8 (10.0)     1                    \-
  16--18                                                                                                                                                      197   36 (18.3)    2.01 (0.89--4.5)     0.093
  19--21                                                                                                                                                      104   16 (15.4)    1.64 (0.66--4.04)    0.286
  \>21                                                                                                                                                        43    9 (20.9)     2.38 (0.85--6.71)    0.101
  **Sexually active (last 3 months)**                                                                                                                                                                 
  No                                                                                                                                                          55    4 (7.3)      1                    \-
  Yes                                                                                                                                                         369   65 (17.6)    2.73 (0.95--7.81)    0.062
  **Condom use (at last sexual encounter)**[^**@**^](#t003fn005){ref-type="table-fn"}                                                                                                                 
  No                                                                                                                                                          229   47 (20,5)    1.75 (0.94--3.16)    0.050
  Yes                                                                                                                                                         140   18 (12.9)    1                    \-
  **Lifetime n° of sex partners**                                                                                                                                                                     
  1                                                                                                                                                           112   13 (11.6)    1                    \-
  2--3                                                                                                                                                        186   32 (17.2)    1.58 (0.79--3.16)    0,194
  \> 3                                                                                                                                                        126   24 (19.0)    1.79 (0.86--3.71)    0,117
  **N° of sex partners in the last 3 months**                                                                                                                                                         
  0                                                                                                                                                           25    0 (0.0)      1                    \-
  \> = 1                                                                                                                                                      399   69 (17.3)    N/A                  **0.010**
  **Recent vaginal sex**[^**%**^](#t003fn007){ref-type="table-fn"}                                                                                                                                    
  No                                                                                                                                                          343   49 (14.3)    1                    \-
  Yes                                                                                                                                                         81    20 (24.7)    2.73 (0.95--7.81)    **0.024**
  **Sexual risk taking**[^**€**^](#t003fn008){ref-type="table-fn"}                                                                                                                                    
  Low                                                                                                                                                         167   25 (15.0)    1                    \-
  Medium                                                                                                                                                      155   30 (19.4)    1.36 (0.76--2.44)    0.297
  High                                                                                                                                                        102   14 (13.7)    0.90 (0.45--1.83)    0.779
  **Estimated frequency of sexual encounters in last 3 months**[^**@**^](#t003fn005){ref-type="table-fn"}^**,**^ [^**&**^](#t003fn006){ref-type="table-fn"}                                           
  0                                                                                                                                                           55    4 (7.3)      1                    \-
  \< 10 times                                                                                                                                                 137   18 (13.1)    1.93 (0.62--5.98)    0.255
  11--30 times                                                                                                                                                129   24 (18.6)    2.91 (0.96--8.84)    0.059
  \> 30 times                                                                                                                                                 98    23 (23.5)    3.91 (1.27--11.98)   **0.017**
  **HIV status partner**[^**@**^](#t003fn005){ref-type="table-fn"}^**,**^                                                                                                                             
  HIV positive                                                                                                                                                38    3 (7.9)      1                    \-
  HIV negative                                                                                                                                                250   52 (20.8)    3.06 (0.91--10.36)   0.072
  Unknown                                                                                                                                                     79    10 (12.6)    1.69 (0.44--6.54)    0.447
  **Estimated frequency of unprotected sex in last 3 months**                                                                                                                                         
  No sexual contacts                                                                                                                                          55    4 (7.3)      1                    \-
  Never unprotected                                                                                                                                           104   12 (11.5)    1.66 (0.51--5.42)    0.399
  \< 10 times                                                                                                                                                 88    14 (15.9)    2.41 (0.75--7.75)    0.139
  \> = 10 times                                                                                                                                               177   39 (22.0)    3.60 (1.23--10.59)   **0.020**
  **New partner (within 3 months)**                                                                                                                                                                   
  No                                                                                                                                                          378   60 (15.9)    1                    \-
  Yes                                                                                                                                                         46    9 (19.6)     1.29 (0.59--2.81)    0.523
  **Circumcision status partner**[^**@**^](#t003fn005){ref-type="table-fn"}^**,**^                                                                                                                    
  Circumcised                                                                                                                                                 240   38 (15.8)    1                    \-
  No/don't know Not circumcised/don't know                                                                                                                    129   27 (20.9)    1.41 (0.81--2.43)    0.222
  **Female sex worker**                                                                                                                                                                               
  Yes                                                                                                                                                         30    6 (20.0)     1                    \-
  No                                                                                                                                                          394   64 (16.2)    1.03 (0.38--2.97)    0.952
  **Vaginal practices**                                                                                                                                                                               
  **Washing inside the vagina when bathing**                                                                                                                                                          
  No                                                                                                                                                          176   15 (8.5)     1                    \-
  Yes                                                                                                                                                         248   54 (21.8)    2.99 (1.63--5.49)    **\<0.001**
  **Drying the vagina before sex**                                                                                                                                                                    
  Yes                                                                                                                                                         10    4 (40.0)     1                    \-
  No                                                                                                                                                          414   65 (15.7)    3.58 (0.98--13.04)   0.053
  **Washed inside the vagina recently (morning or evening before study visit)**                                                                                                                       
  No                                                                                                                                                          231   28 (12.1)    1                    \-
  Yes                                                                                                                                                         193   41 (21.2)    1.96 (1.16--3.30)    **0.012**
  **Products to wash/clean/dry/tighten the vagina**                                                                                                                                                   
  None                                                                                                                                                        153   13 (8.5)     1                    \-
  Water/fingers only or water/soap                                                                                                                            211   44 (20.9)    2.84 (1.47--5.48)    **0.002**
  Cloth                                                                                                                                                       48    9 (18.8)     2.49 (0.99--6.24)    0.053
  Lemon juice/detergents                                                                                                                                      12    3 (25.0)     3.59 (0.86--14.92)   0.079
  **Cleaning the vagina after sexual intercourse**                                                                                                                                                    
  No                                                                                                                                                          227   28 (12.3)    1                    \-
  Yes                                                                                                                                                         197   41 (20.8)    1.87 (1.11--3.16)    **0.019**
  **Cervicovaginal signs and symptoms**                                                                                                                                                               
  **Ectopy**[^**¶**^](#t003fn009){ref-type="table-fn"}                                                                                                                                                
  No                                                                                                                                                          226   34 (15.0)    1                    \-
  Yes                                                                                                                                                         197   34 (17.3)    1.18 (0.70--1.98)    0.536
  **Degree of ectopy**[^**¶**^](#t003fn009){ref-type="table-fn"}                                                                                                                                      
  Absent                                                                                                                                                      226   34 (15.0)    1                    \-
  Small                                                                                                                                                       53    8 (15.1)     1.00 (0.44--2.32)    0.993
  Moderate                                                                                                                                                    139   24 (17.3)    1.18 (0.67--2.09)    0.573
  Large                                                                                                                                                       5     2 (40.0)     3.77 (0.61--23.4)    0.155
  **Colposcopic findings**[^**§**^](#t003fn010){ref-type="table-fn"}^**,**^[^**¶**^](#t003fn009){ref-type="table-fn"}                                                                                 
  No                                                                                                                                                          380   59 (15.5)    1                    \-
  Yes                                                                                                                                                         43    10 (23.3)    1.65 (0.77--3.53)    0.197
  **Cervical mucus**                                                                                                                                                                                  
  No                                                                                                                                                          270   39 (14.4)    1                    \-
  Mild to moderate                                                                                                                                            140   28 (20.0)    1.48 (0.87--2.53)    0.151
  Abundant                                                                                                                                                    14    2 (14.3)     0.99 (0.21--4.58)    0.987
  **Reported abnormal discharge**                                                                                                                                                                     
  No                                                                                                                                                          399   64 (16.0%)   1                    \-
  Yes                                                                                                                                                         25    5 (20%)      1.31 (0.47--3.61)    0.604
  **Vaginal discharge on speculum**                                                                                                                                                                   
  No                                                                                                                                                          332   52 (15.7)    1                    \-
  Yes                                                                                                                                                         92    17 (18.5)    0.82 (0.45--1.50)    0.518
  **Vaginal epithelial abnormalities**                                                                                                                                                                
  No                                                                                                                                                          419   67 (16.0)    1                    \-
  Yes                                                                                                                                                         5     2 (40.0)     3.50 (0.57--21.36)   0.174
  **Cervical epithelial abnormalities**                                                                                                                                                               
  No                                                                                                                                                          379   64 (16.9)    1                    \-
  Yes                                                                                                                                                         45    5 (11.1)     0.62 (0.23--1.62)    0.325
  **Red blood cells in urine**                                                                                                                                                                        
  No                                                                                                                                                          358   58 (16.2)    1                    \-
  Yes                                                                                                                                                         66    11 (16.7)    1.03 (0.51--2.10)    0.925
  **White blood cells in urine**                                                                                                                                                                      
  No                                                                                                                                                          328   56 (17.1)    1                    \-
  Yes                                                                                                                                                         96    13 (13.5)    0.76 (0.40--1.46)    0.411
  **Microbiological factors**                                                                                                                                                                         
  **BV visit 1 (Amsel criteria)**                                                                                                                                                                     
  No BV                                                                                                                                                       346   61 (17.6)    1                    \-
  BV                                                                                                                                                          78    8 (10.3)     0.53 (0.24--1.17)    0.116
  **BV (Nugent)** [^**¶**^](#t003fn009){ref-type="table-fn"}                                                                                                                                          
  No BV (Nugent 0--3)                                                                                                                                         217   37 (17.1)    1                    \-
  Intermediate (Nugent 4--6)                                                                                                                                  29    6 (20.7)     1.30 (0.60--2.83)    0.507
  BV (Nugent 7--10)                                                                                                                                           137   13 (9.5)     0.29 (0.12--0.70)    **0.006**
  **Reproductive tract infection (RTI)**                                                                                                                                                              
  No RTI                                                                                                                                                      352   60 (17.0)    1                    \-
  1 or more RTI                                                                                                                                               60    8 (13.3)     0.75 (0.34--1.66)    0.475
  \>1 RTI                                                                                                                                                     12    1 (8.3)      0.44 (0.06--3.50)    0.439
  **Syphilis**                                                                                                                                                                                        
  No                                                                                                                                                          415   69 (16.6)    1                    \-
  Yes                                                                                                                                                         9     0 (0.0)      N/A                  **0.001**
  ***Chlamydia trachomatis***                                                                                                                                                                         
  No                                                                                                                                                          382   62           1                    \-
  Yes                                                                                                                                                         42    7            1.03 (0.44--2.43)    0.942
  ***Neisseria gonorrhoeae***                                                                                                                                                                         
  No                                                                                                                                                          415   69 (16.6)    1                    \-
  Yes                                                                                                                                                         9     0 (0.0)      N/A                  **0.001**
  ***Trichomonas vaginalis***                                                                                                                                                                         
  No                                                                                                                                                          390   66 (16.9)    1                    \-
  Yes                                                                                                                                                         26    3 (11.5)     0.64 (0.19--2.20)    0.478
  ***Candida albicans* (qPCR)**                                                                                                                                                                       
  No                                                                                                                                                          375   50 (13.3)    1                    \-
  Yes                                                                                                                                                         46    17 (37.0)    3.81 (1.95--7.44)    **\<0.001**
  ***Escherichia coli* (qPCR)**                                                                                                                                                                       
  No                                                                                                                                                          354   89 (25.1)    1                    \-
  Yes                                                                                                                                                         67    29 (43.3)    2.27 (1.33--3.90)    **0.003**
  **HSV-2 serology**                                                                                                                                                                                  
  No                                                                                                                                                          276   42 (15.2%)   1                    \-
  Yes                                                                                                                                                         147   27 (18.4%)   1.25 (0.74--2.13)    0.404
  **Vaginal pH**                                                                                                                                                                                      
  \< 4.4                                                                                                                                                      126   15 (11.9)    1                    \-
  4.4--5.3                                                                                                                                                    240   42 (17.5)    1.57 (0.83--2.96)    0.163
  5.4 and more                                                                                                                                                58    12 (20.7)    1.93 (0.84--4.44)    0.122
  **PSA present**                                                                                                                                                                                     
  No                                                                                                                                                          233   31 (13.3)    1                    \-
  Yes                                                                                                                                                         181   38 (21.0)    1.73 (1.03--2.91)    **0.039**
  **Systemic antibiotics visit 1**                                                                                                                                                                    
  No                                                                                                                                                          341   62 (18.1)    1                    \-
  Yes                                                                                                                                                         83    7 (8.4)      0.41 (0.18--0.94)    **0.036**
  **Systemic antibiotics screening visit**                                                                                                                                                            
  No                                                                                                                                                          391   68 (17.4)    1                    \-
  Yes                                                                                                                                                         33    1 (3.0)      0.15 (0.02--1.11)    0.063

^\*^bold: significant at the 5% level

^£^completed secondary school, or post-secondary school

^££^Primary school (completed or not), secondary school but not completed

^\#^Socio-economic-status was constructed from total income, type of housing, type of toilet

^@^with partners within three months prior to enrolment

^&^missing data for 5

^%^sex morning or evening before visit &

^€^low risk: 1 or no partners in last year and did not have any partner (in the last 3 months) with multiple partners and age first sex at least 15 years; medium risk: 2 partners last year or had at least one sexual partner (in the last 3 months) who had multiple partners; high risk: sex worker or at least 3 partners last year or at had at least one sexual partner with HIV in the last 3 months or age first sex less than 15 years; N/A, no odds ratio due to no cases in one category

^¶^data missing for 1 (ectopy, colposcopic findings, HSV-2 serology), 3 (*C*. *albicans*, *E*. *coli*), 8 (*T*. *vaginalis*), 41 (BV Nugent, unreadable slides)

^§^petechiae (6 GBS cases/20), abrasion (2 GBS cases/5), erythema (1 GBS case/10), laceration (1 GBS case/4); BV, bacterial vaginosis; IUD, intrauterine device.

10.1371/journal.pone.0148052.t004

###### Sociodemographic characteristics, reproductive health, sexual behavior, vaginal practices, vaginal signs & symptoms, and microbiological associations with vaginal *E*. *coli* carriage (univariable analysis).

![](pone.0148052.t004){#pone.0148052.t004g}

                                                                                                                                                              n     *E*. *coli* + n (%)   Crude OR (95% CI)    p-value[\*](#t004fn001){ref-type="table-fn"}
  ----------------------------------------------------------------------------------------------------------------------------------------------------------- ----- --------------------- -------------------- ----------------------------------------------
                                                                                                                                                              421   118 (28.0)                                 
  **Sociodemographic characteristics**                                                                                                                                                                         
  **City (Country)**                                                                                                                                                                                           
  Mombasa (Kenya)                                                                                                                                             164   39 (23.6)             0.87 (0.54--1.41)    0.569
  Kigali (Rwanda)                                                                                                                                             60    27 (45.0)             2.28 (1.25--4.15)    **0.007**
  Johannesburg (SA)                                                                                                                                           197   52 (26.5)             1                    \-
  **Age (years)**                                                                                                                                                                                              
  \<18                                                                                                                                                        58    12 (20.7)             0.73 (0.36--1.47)    0.376
  18--24                                                                                                                                                      147   49 (33.3)             1.40 (0.88--2.20)    0.154
  \>24                                                                                                                                                        216   57 (26.4)             1                    \-
  **Educational level**                                                                                                                                                                                        
  Higher educational level[^£^](#t003fn002){ref-type="table-fn"}                                                                                              187   56 (29.9)             1                    \-
  Lower educational level[^££^](#t004fn003){ref-type="table-fn"}                                                                                              234   62 (26.5)             0.84 (0.55--1.29)    0.434
  **Marital status**                                                                                                                                                                                           
  Never married                                                                                                                                               240   71 (29.6)             1                    \-
  Married                                                                                                                                                     147   37 (25.2)             0.80 (0.50--1.27)    0.348
  Separated/divorced/widowed                                                                                                                                  34    10 (29.4)             0.99 (0.45--2.18)    0.984
  **Socio-economic status**[^**\#**^](#t004fn004){ref-type="table-fn"}                                                                                                                                         
  Low                                                                                                                                                         106   27 (25.5)             1                    \-
  Medium                                                                                                                                                      163   46 (28.2)             1.15 (0.66--2.00)    0.620
  High                                                                                                                                                        152   45 (29.6)             1.23 (0.70--2.15)    0.467
  **Reproductive health**                                                                                                                                                                                      
  **Pregnant**                                                                                                                                                                                                 
  No                                                                                                                                                          363   104 (28.7)            1                    \-
  Yes                                                                                                                                                         58    14 (24.1)             0.79 (0.42--1.51)    0.478
  **Parity**                                                                                                                                                                                                   
  0                                                                                                                                                           149   35 (23.5)             1                    \-
  1--2                                                                                                                                                        209   62 (29.7)             1.37 (0.85--2.22)    0.196
  \>2                                                                                                                                                         63    21 (33.3)             1.63 (0.85--3.11)    0.139
  **Gravity**                                                                                                                                                                                                  
  0                                                                                                                                                           118   25 (21.2)             1                    \-
  1--2                                                                                                                                                        208   63 (30.3)             1.62 (0.95--2.75)    0.077
  \>2                                                                                                                                                         95    30 (31.6)             1.72 (0.93--3.19)    0.087
  **Regular cycle**                                                                                                                                                                                            
  Yes                                                                                                                                                         254   65 (25.6)             1                    \-
  No/unknown                                                                                                                                                  167   54 (33.3)             1.42 (0.92--2.18)    0.111
  **Menstrual cycle**                                                                                                                                                                                          
  No cycle                                                                                                                                                    194   58 (29.9)             1                    \-
  With cycle                                                                                                                                                  227   60 (26.4)             0.84 (0.55--1.29)    0.430
  **Contraceptive**                                                                                                                                                                                            
  None                                                                                                                                                        72    20 (27.8)             1                    \-
  Condom only                                                                                                                                                 106   28 (26.4)             0.93 (0.48--1.83)    0.841
  Others (hormones/IUD/sterilisation/pregnant)                                                                                                                243   70 (28.8)             1.05 (0.59--1.89)    0.865
  **Currently breastfeeding**                                                                                                                                                                                  
  No                                                                                                                                                          387   106 (27.4)            1                    \-
  Yes                                                                                                                                                         34    12 (35.3)             1.45 (0.69--3.03)    0.327
  **Sexual behaviour**                                                                                                                                                                                         
  **Age at first sexual encounter (years)**                                                                                                                                                                    
  \<16                                                                                                                                                        79    29 (36.7)             1                    \-
  16--18                                                                                                                                                      197   52 (26.4)             0.62 (0.35--1.08)    0.090
  19--21                                                                                                                                                      103   26 (25.2)             0.58 (0.31--1.10)    0.096
  \>21                                                                                                                                                        42    11 (26.2)             0.61 (0.27--1.40)    0.224
  **Sexually active (last 3 months)**                                                                                                                                                                          
  No                                                                                                                                                          55    16 (29.1)             1                    \-
  Yes                                                                                                                                                         366   102 (27.9)            0.94 (0.50--1.76)    0.851
  **Condom use (at last sexual encounter)**                                                                                                                                                                    
  No                                                                                                                                                          283   68 (24.0)             1.80 (1.16--2.79)    **0.009**
  Yes                                                                                                                                                         138   50 (36.2)             1                    \-
  **Lifetime n° of sex partners**                                                                                                                                                                              
  1                                                                                                                                                           110   28 (25.5)             1                    \-
  2--3                                                                                                                                                        185   42 (22.7)             0.86 (0.50--1.49)    0.591
  \> 3                                                                                                                                                        126   48 (38.1)             1.80 (1.03--3.15)    **0.039**
  **N° of sex partners in the last 3 months**                                                                                                                                                                  
  0                                                                                                                                                           25    6 (24.0)              1                    \-
  \> = 1                                                                                                                                                      396   112 (28.3)            1.25 (0.49--3.21)    0.644
  **Recent vaginal sex**[^**%**^](#t004fn007){ref-type="table-fn"}                                                                                                                                             
  No                                                                                                                                                          340   91 (26.8)             1                    \-
  Yes                                                                                                                                                         81    27 (33.3)             1.37 (0.81--2.30)    0.238
  **Sexual risk taking**[^**€**^](#t004fn008){ref-type="table-fn"}                                                                                                                                             
  Low                                                                                                                                                         167   44 (26.3)             1                    \-
  Medium                                                                                                                                                      152   37 (22.4)             0.90 (0.54--1.49)    0.681
  High                                                                                                                                                        102   37 (36.3)             1.59 (0.94--2.71)    0.086
  **Estimated frequency of sexual encounters in last 3 months**[^**@**^](#t004fn005){ref-type="table-fn"}^**,**^ [^**&**^](#t004fn006){ref-type="table-fn"}                                                    
  0                                                                                                                                                           55    16 (29.1)             1                    \-
  \< 10 times                                                                                                                                                 135   31 (23.0)             0.73 (0.36--1.47)    0.376
  11--30 times                                                                                                                                                128   43 (33.6)             1.23 (0.62--2.45)    0.550
  \> 30 times                                                                                                                                                 98    27 (27.6)             0.93 (0.45--1.93)    0.839
  **HIV status partner**[^**@**^](#t004fn005){ref-type="table-fn"}                                                                                                                                             
  HIV positive                                                                                                                                                38    11 (28.9)             1                    \-
  HIV negative                                                                                                                                                247   63 (25.5)             0.84 (0.39--1.79)    0.653
  Unknown                                                                                                                                                     79    28 (35.4)             1.35 (0.58--3.12)    0.486
  **Estimated frequency of unprotected sex in last 3 months**                                                                                                                                                  
  No sexual contacts                                                                                                                                          55    16 (29.1)             1                    \-
  Never unprotected                                                                                                                                           102   34 (33.3)             1.22 (0.60--2.49)    0.586
  \< 10 times                                                                                                                                                 87    19 (21.8)             0.68 (0.31--1.48)    0.330
  \> = 10 times                                                                                                                                               177   49 (27.7)             0.93 (0.48--1.82)    0.839
  **New partner (within 3 months)**                                                                                                                                                                            
  No                                                                                                                                                          375   96 (25.6)             1                    \-
  Yes                                                                                                                                                         46    22 (47.8)             2,66 (1.43--4.97)    **0.002**
  **Circumcision status partner**[^**@**^](#t004fn005){ref-type="table-fn"}                                                                                                                                    
  Circumcised                                                                                                                                                 238   62 (26.1)             1                    \-
  Not circumcised/don't know                                                                                                                                  128   40 (31.3)             1.29 (0.80--2.07)    0.291
  **Female sex worker**                                                                                                                                                                                        
  No                                                                                                                                                          391   97 (24.8)             1                    \-
  Yes                                                                                                                                                         30    21 (70.0)             7.07 (3.13--15.96)   **\<0.001**
  **Vaginal practices**                                                                                                                                                                                        
  **Washing inside the vagina when bathing**                                                                                                                                                                   
  No                                                                                                                                                          175   44 (25.1)             1                    \-
  Yes                                                                                                                                                         246   74 (30.1)             1.28 (0.83--1.98)    0.267
  **Drying the vagina before sex**                                                                                                                                                                             
  No                                                                                                                                                          411   114 (27.3)            1                    \-
  Yes                                                                                                                                                         10    4 (40.0)              1.74 (0.48--6.27)    0.399
  **Washed inside the vagina recently (morning or evening before study visit)**                                                                                                                                
  No                                                                                                                                                          229   64 (27.9)             1                    \-
  Yes                                                                                                                                                         192   54 (28.1)             1.01 (0.66--1.55)    0.968
  **Products to wash/clean/dry/tighten the vagina**                                                                                                                                                            
  None                                                                                                                                                        153   40 (26.1)             1                    \-
  Water/fingers only or water/soap                                                                                                                            210   59 (28.1)             1.10 (0.69--1.77)    0.680
  Cloth                                                                                                                                                       46    16 (34.8)             1.51 (0.74--3.05)    0.255
  Lemon juice/detergents                                                                                                                                      12    3 (25.0)              0.94 (0.24--3.65)    0.931
  **Cleaning the vagina after sexual intercourse**                                                                                                                                                             
  No                                                                                                                                                          226   61 (27.0)             1                    \-
  Yes                                                                                                                                                         195   57 (29.2)             1.12 (0.73--1.71)    0.610
  **Cervicovaginal signs and symptoms**                                                                                                                                                                        
  **Ectopy**[^**¶**^](#t003fn009){ref-type="table-fn"}                                                                                                                                                         
  No                                                                                                                                                          224   49 (21.9)             1                    \-
  Yes                                                                                                                                                         196   69 (35.2)             1.94 (1.26--2.99)    **0.003**
  **Degree of ectopy**[^**¶**^](#t003fn009){ref-type="table-fn"}                                                                                                                                               
  Absent                                                                                                                                                      224   49 (21.9)             1                    \-
  Small                                                                                                                                                       52    22 (42.3)             2.62 (1.39--4.94)    **0.003**
  Moderate                                                                                                                                                    139   46 (33.1)             1.77 (1.10--2.84)    **0.019**
  Large                                                                                                                                                       5     1 (20.0)              0.89 (0.10--8.17)    0.920
  **Colposcopic findings**[^**§**^](#t004fn010){ref-type="table-fn"}^**,**^ [^**¶**^](#t004fn009){ref-type="table-fn"}                                                                                         
  No                                                                                                                                                          377   102 (27.1)            1                    \-
  Yes                                                                                                                                                         43    16 (37.2)             1.60 (0.83--3.09)    0.163
  **Cervical mucus**                                                                                                                                                                                           
  No                                                                                                                                                          269   67 (24.9)             1                    \-
  Mild to moderate                                                                                                                                            138   47 (34.1)             1.56 (1.00--2.44)    0.052
  Abundant                                                                                                                                                    14    4 (28.6)              1.21 (0.37--3.97)    0.758
  **Reported abnormal discharge**                                                                                                                                                                              
  No                                                                                                                                                          396   112 (28.3)            1                    \-
  Yes                                                                                                                                                         25    6 (24.0)              0.80 (0.31--2.06)    0.644
  **Vaginal discharge on speculum**                                                                                                                                                                            
  No                                                                                                                                                          331   85 (25.7)             1                    \-
  Yes                                                                                                                                                         90    33 (36.7)             1.68 (1.02--2.75)    **0.041**
  **Vaginal epithelial abnormalities**                                                                                                                                                                         
  No                                                                                                                                                          416   116 (27.9)            1                    \-
  Yes                                                                                                                                                         5     2 (40.0)              1.72 (0.28--10.45)   0.554
  **Cervical epithelial abnormalities**                                                                                                                                                                        
  No                                                                                                                                                          377   105 (27.9)            1                    \-
  Yes                                                                                                                                                         44    13 (29.5)             1.09 (0.55--2.16)    0.813
  **Red blood cells in urine**                                                                                                                                                                                 
  No                                                                                                                                                          355   101 (28.5)            1                    \-
  Yes                                                                                                                                                         66    17 (25.8)             0.87 (0.48--1.59)    0.655
  **White blood cells in urine**                                                                                                                                                                               
  No                                                                                                                                                          325   81 (24.9)             1                    \-
  Yes                                                                                                                                                         96    37 (38.5)             1.89 (1.17--3.06)    **0.010**
  **Microbiological factors**                                                                                                                                                                                  
  **BV visit 1 (Amsel criteria)**                                                                                                                                                                              
  No BV                                                                                                                                                       344   99 (28.8)             1                    \-
  BV                                                                                                                                                          77    19 (24.7)             0.81 (0.46--1.43)    0.469
  **BV visit 1 (Nugent)** [^**¶**^](#t004fn009){ref-type="table-fn"}                                                                                                                                           
  No BV (Nugent 0--3)                                                                                                                                         217   60 (27.6)             1                    \-
  Intermediate (Nugent 4--6)                                                                                                                                  29    15 (51.7)             2.80 (1.28--6.16)    **0.010**
  BV (Nugent 7--10)                                                                                                                                           137   33 (24.1)             0.83 (0.51--1.36)    0.459
  **GBS**                                                                                                                                                                                                      
  No                                                                                                                                                          354   89 (25.1)             1                    \-
  Yes                                                                                                                                                         67    29 (43.3)             2.27 (1.33--3.90)    **0.003**
  **Reproductive tract infection (RTI)**                                                                                                                                                                       
  No RTI                                                                                                                                                      349   96 (27.5)             1                    \-
  1 or more RTI                                                                                                                                               60    19 (31.7)             1.22 (0.68--2.21)    0.508
  \>1 RTI                                                                                                                                                     12    3 (25.0)              0.88 (0.23--3.31)    0.848
  **Syphilis**                                                                                                                                                                                                 
  No                                                                                                                                                          412   117 (28.4)            1                    \-
  Yes                                                                                                                                                         9     1 (11.1)              0.32 (0.04--2.55)    0.279
  ***Chlamydia trachomatis***                                                                                                                                                                                  
  No                                                                                                                                                          379   107 (28.2)            1                    \-
  Yes                                                                                                                                                         42    11 (26.2)             0.90 (0.44--1.86)    0.780
  ***Neisseria gonorrhoeae***                                                                                                                                                                                  
  No                                                                                                                                                          412   114 (27.7)            1                    \-
  Yes                                                                                                                                                         9     4 (44.4)              2.09 (0.55--7.93)    0.278
  ***Trichomonas vaginalis***[^**¶**^](#t004fn009){ref-type="table-fn"}                                                                                                                                        
  No                                                                                                                                                          387   105 (27.1)            1                    \-
  Yes                                                                                                                                                         26    11 (42.3)             1.97 (0.88--4.43)    0.101
  ***Candida albicans* (qPCR)**                                                                                                                                                                                
  No                                                                                                                                                          375   102 (27.2)            1                    \-
  Yes                                                                                                                                                         46    16 (34.8)             1.43 (0.75--2.73)    0.282
  **HSV-2 serology**[^**¶**^](#t004fn009){ref-type="table-fn"}                                                                                                                                                 
  No                                                                                                                                                          274   80 (29.2)             1                    \-
  Yes                                                                                                                                                         146   38 (26.0)             0.85 (0.54--1.34)    0.492
  **Vaginal pH**                                                                                                                                                                                               
  \< 4.4                                                                                                                                                      125   34 (27.2)             1                    \-
  4.4--5.3                                                                                                                                                    237   65 (27.4)             1.01 (0.62--1.65)    0.963
  5.4 and more                                                                                                                                                58    19 (32.8)             1.30 (0.66--2.56)    0.441
  **PSA present**                                                                                                                                                                                              
  No                                                                                                                                                          231   69 (29.9)             1                    \-
  Yes                                                                                                                                                         180   48 (26.7)             0.85 (0.55--1.32)    0.475
  **Systemic antibiotics visit 1**                                                                                                                                                                             
  No                                                                                                                                                          338   98 (29.0)             1                    \-
  Yes                                                                                                                                                         83    20 (24.0)             0.78 (0.45--2.36)    0.374
  **Systemic antibiotics screening visit**                                                                                                                                                                     
  No                                                                                                                                                          388   111 (28.6)            1                    \-
  Yes                                                                                                                                                         33    7 (21.2)              0.67 (0.28--1.59)    0.366

^\*^Bold: significant at the 5% level

^£^completed secondary school, or post-secondary school

^££^Primary school (completed or not), secondary school but not completed

^\#^Socio-economic-status was constructed from total income, type of housing, type of toilet

^@^with partners within three months prior to enrolment

^&^missing data for 5

^%^sex morning or evening before visit

^€^low risk: 1 or no partners in last year and did not have any partner (in the last 3 months) with multiple partners and age first sex at least 15 years; medium risk: 2 partners last year or had at least one sexual partner (in the last 3 months) who had multiple partners; high risk: sex worker or at least 3 partners last year or at had at least one sexual partner with HIV in the last 3 months or age first sex less than 15 years; N/A, no odds ratio due to no cases in one category

^¶^data missing for 1 (ectopy, colposcopic findings, HSV-2 serology), 8 (*T*. *vaginalis*), 38 (BV Nugent, unreadable slides)

^§^petechiae (6 *E*. *coli* cases/20), abrasion (2 *E*. *coli* cases/5), erythema (3 *E*. *coli* cases/10), laceration (2 *E*. *coli* cases/4), ulcer (2 E. coli cases/6), ecchymosis (2 *E*. *coli* cases/6); BV, bacterial vaginosis.

In our final multivariable GBS model ([Table 5](#pone.0148052.t005){ref-type="table"}), BV by Nugent score remained significantly negatively associated with GBS carriage (AOR, 0.43; 95% CI, 0.21--0.88; p = 0.022), and a positive association was observed for vaginal *Candida albicans* carriage (AOR, 3.25; 95% CI, 1.50--7.06; p = 0.003), vaginal *E*. *coli* carriage (AOR, 2.01; 95% CI, 1.10--3.80; p = 0.023), recent vaginal intercourse (AOR, 2.63; 95% CI, 1.35--5.15; p = 0.005), and currently washing the vagina (AOR, 2.26; 95% CI, 1.16--4.37; p = 0.016).

10.1371/journal.pone.0148052.t005

###### Multivariable associations with vaginal GBS carriage.

![](pone.0148052.t005){#pone.0148052.t005g}

                                                                             n     GBS+ (%)    adjusted OR (95% CI)   p-value[^\$^](#t005fn001){ref-type="table-fn"}
  -------------------------------------------------------------------------- ----- ----------- ---------------------- ------------------------------------------------
                                                                             424   69 (16.3)                          
  **Recent vaginal sex**[^**%**^](#t005fn003){ref-type="table-fn"}                                                    
  No                                                                         343   49 (14.3)   1                      \-
  Yes                                                                        81    20 (24.7)   2.63 (1.35--5.15)      **0.005**
  **Washing inside the vagina**[^**\#**^](#t005fn002){ref-type="table-fn"}                                            
  No                                                                         176   15 (8.5)    1                      \-
  Yes                                                                        248   54 (21.8)   2.26 (1.16--4.37)      **0.016**
  **BV (Nugent)**[^**¶**^](#t005fn004){ref-type="table-fn"}                                                           
  No BV (Nugent 0--3)                                                        217   37 (17.1)   1                      \-
  Intermediate (Nugent 4--6)                                                 29    6 (20.7)    0.93 (0.33--2.64)      0.898
  BV (Nugent 7--10)                                                          137   13 (9.5)    0.43 (0.21--0.88)      **0.022**
  ***Candida albicans* (qPCR)**[^**¶**^](#t005fn004){ref-type="table-fn"}                                             
  No                                                                         375   50 (13.3)   1                      \-
  Yes                                                                        46    17 (37.0)   3.25 (1.50--7.06)      **0.003**
  ***Escherichia coli*** [^**¶**^](#t005fn004){ref-type="table-fn"}                                                   
  No                                                                         303   38 (12.5)   1                      \-
  Yes                                                                        118   29 (24.6)   2.01 (1.10--3.80)      **0.023**

^\$^bold, significant at the 5% level

^\#^when having shower or bath

^%^morning or evening before study visit

^¶^data missing for 3 (*C*. *albicans*, *E*. *coli*), 41 (BV, unreadable slides).

In our multivariable *E*. *coli* model, an intermediate Nugent score remained significantly negatively associated with vaginal *E*. *coli* carriage (AOR, 2.61; 95% CI, 1.15--5.94; p = 0.023), and a positive association was observed with working as a FSW (AOR, 7.83; 95% CI, 2.88--21.30; p\<0.001), vaginal GBS carriage (AOR, 2.05; 95% CI, 1.09--3.83; p = 0.025), and cervical ectopy (AOR, 1.64; 95% CI, 1.01--2.68; p = 0.046) ([Table 6](#pone.0148052.t006){ref-type="table"}).

10.1371/journal.pone.0148052.t006

###### Multivariable associations with vaginal *E*. *coli* carriage.

![](pone.0148052.t006){#pone.0148052.t006g}

                                                              n     *E*. *coli* + (%)   adjusted OR (95% CI)   p-value[^\$^](#t006fn001){ref-type="table-fn"}
  ----------------------------------------------------------- ----- ------------------- ---------------------- ------------------------------------------------
                                                              421   118 (25.2)                                 
  **Condom use (at last sexual encounter)**                                                                    
  No                                                          283   68 (24.0)           1.53 (0.92--2.56)      0.104
  Yes                                                         138   50 (36.2)           1.0                    \-
  **Female sex worker**                                                                                        
  No                                                          391   97 (24.8)           1                      \-
  Yes                                                         30    21 (70.0)           7.83 (2.88--21.30)     **\<0.001**
  **Ectopy** [^**¶**^](#t006fn002){ref-type="table-fn"}                                                        
  No                                                          224   49 (21.9)           1                      \-
  Yes                                                         196   69 (35.2)           1.64 (1.01--2.68)      **0.046**
  **Vaginal discharge on speculum**                                                                            
  No                                                          331   85 (25.7)           1                      \-
  Yes                                                         90    33 (36.7)           1.63 (0.92--2.88)      0.095
  **BV (Nugent)**[^**¶**^](#t006fn002){ref-type="table-fn"}                                                    
  No BV (Nugent 0--3)                                         217   60 (27.6)           1                      \-
  Intermediate (Nugent 4--6)                                  29    15 (51.7)           2.61 (1.15--5.94)      **0.023**
  BV (Nugent 7--10)                                           137   33 (24.1)           0.66 (0.38--1.15)      0.140
  **GBS**                                                                                                      
  No                                                          354   89 (25.1)           1                      \-
  Yes                                                         67    29 (43.3)           2.05 (1.09--3.83)      **0.025**

^\$^bold, significant at the 5% level

^¶^data missing for 1 (ectopy), 38 (BV, unreadable slides).

Discussion {#sec022}
==========

Group B streptococci (GBS) and *E*. *coli* account for the majority of EOS cases worldwide.

Vaginal carriage of GBS and *E*. *coli* is considered a prerequisite for GBS or *E*. *coli* transmission to the neonate in GBS EOS and *E*. *coli* EOS, respectively. However, epidemiological data of vaginal GBS and *E*. *coli* carriage, which are essential for the development and implementation of prevention strategies, are very limited in sub-Saharan Africa (SSA) \[[@pone.0148052.ref016], [@pone.0148052.ref017]\].

In this study, we aimed to present vaginal GBS and *E*. *coli* carriage rates, GBS serotype distribution and define risk factors for carriage in populations from three SSA countries.

Vaginal GBS and *E*. *coli* carriage rates {#sec023}
------------------------------------------

We found a vaginal GBS carriage rate of 20.2% and 23.2% in the Kenyan and South African reference groups (adult, non-pregant, HIV-negative women at average risk of HIV), respectively. Compared to these reference groups, adolescents in our study were found to have lower GBS carriage rates: 3.6% of the Kenyan and 0% of the SA adolescents carried GBS vaginally. Other studies report conflicting associations between age and vaginal GBS carriage \[[@pone.0148052.ref039]--[@pone.0148052.ref047]\]. All of these studies (except for \[[@pone.0148052.ref044]\]) report on pregnant women. Interestingly, when we compare different age groups (\< 18 years, 18--24 years, \> 24 years) in our Kenyan and SA population, we see no age-group dependent GBS colonization in the pregnant women. However, we do see a statistically significant age-group dependent GBS association in the non-pregnant women, with the lowest and the highest GBS carrier rates in the youngest and the oldest age groups, respectively (Pearson Chi-Square test, data not shown).

The pregnant women in our study population had vaginal GBS carriage rates of 14.3% and 10.0% in Kenya and SA, respectively. This is lower then most other studies reporting (recto)vaginal GBS carriage rates in SSA (see [Table 7](#pone.0148052.t007){ref-type="table"}). Although the CDC recommends rectovaginal sampling for detection of GBS in pregnant women, we only swabbed vaginally, to be able to study the interaction of GBS with the vaginal immune system and vaginal microbiome (to be published). This vaginal sampling may (partly) explain the lower GBS carriage rates found by us, as rectovaginal sampling has been shown to yield higher GBS recovery rates compared to vaginal sampling alone \[[@pone.0148052.ref048], [@pone.0148052.ref049]\]. Furthermore, in contrast to other studies (listed in [Table 7](#pone.0148052.t007){ref-type="table"}) using culturing techniques, we used qPCR without prior enrichment step to detect GBS. Although the CDC allows PCR for the detection of GBS (albeit recommending an enrichment step), this difference with other studies probably does not account (or to a lesser extent) for the lower rates found by us, as PCR (even without an enrichment step) has been shown to be more sensitive than culture \[[@pone.0148052.ref014], [@pone.0148052.ref050]--[@pone.0148052.ref053]\]. A further difference with other studies regards the fact that the pregnant women in our study were up to 14 weeks of gestation, while the other studies listed in [Table 7](#pone.0148052.t007){ref-type="table"} sampled pregnant women at 35--37 weeks of gestation, which also may account for differences, as some authors have reported on varying GBS rates during pregnancy \[[@pone.0148052.ref045]\].

10.1371/journal.pone.0148052.t007

###### Studies reporting (recto)vaginal GBS carriage rates in SSA.

![](pone.0148052.t007){#pone.0148052.t007g}

  Country        Year   n                                                           Population         \% GBS                                                          Sample   Detection   Reference
  -------------- ------ ----------------------------------------------------------- ------------------ --------------------------------------------------------------- -------- ----------- ----------------------------
  Nigeria        1980   588                                                         P, L               19                                                              V        SB+C        \[[@pone.0148052.ref055]\]
  Nigeria        1983   225                                                         P                  20                                                              V        SB+C        \[[@pone.0148052.ref056]\]
  Zimbabwe       1990   89                                                          P                  31                                                              V        SB+C        \[[@pone.0148052.ref057]\]
  Togo           1991   106                                                         P                  4                                                               V, R     SB+C        \[[@pone.0148052.ref058]\]
  Gambia         1994   136                                                         P                  22                                                              V, R     SB+C        \[[@pone.0148052.ref034]\]
  Malawi         2005   97                                                          P                  16.5                                                            V, R     SA          \[[@pone.0148052.ref059]\]
  Mozambique     2008   113                                                         P                  1.8                                                             V, R     SB+C        \[[@pone.0148052.ref060]\]
  Tanzania       2009   300                                                         P                  23.0                                                            V, R     SB+C        \[[@pone.0148052.ref054]\]
  Zimbabwe       2010   780                                                         P                  47, 24, 21[^\#^](#t007fn002){ref-type="table-fn"}               V, R     SB+C        \[[@pone.0148052.ref061]\]
  Malawi         2011   1840                                                        P, HIV+ and HIV-   21.2                                                            V, R     SB+C        \[[@pone.0148052.ref035]\]
  South Africa   2014   661, 621, 595, 521[^\$^](#t007fn003){ref-type="table-fn"}   P                  33.0, 32.7, 28.7, 28.4[^\$^](#t007fn003){ref-type="table-fn"}   V, R     SA          \[[@pone.0148052.ref037]\]
  DR Congo       2015   509                                                         P                  20.2                                                            V        SA          \[[@pone.0148052.ref062]\]

L, women in labor; NP, non-pregnant women; P, pregnant women; V, vaginal swab; R, rectal swab; SB+C, selective broth and culturing; SA, selective agar

^\#^week 20, 26, and delivery, respectively

^\$^week 20--25, week 26--30, week 31--35, and week 37+, respectively.

In the group of HIV positive women, we did not observe any GBS carriers, which is probably explained by the fact that most of the HIV positive women (26/30) received prophylactic cotrimoxazole, which is largely effective against GBS \[[@pone.0148052.ref054]\].

Our reference groups from Kenya and SA had vaginal *E*. *coli* carriage rates of 25.0% and 27.1%, respectively. Compared to other studies from SSA reporting vaginal carriage of *E*. *coli*, these prevalences are higher than the ones reported by Karou and coworkers (2012) and Ekwempu and coworkers (1981), lower than the ones reported by Schellenberg and coworkers (2011) and Cutland and coworkers (2012), and comparable with the prevalence reported by Sagna and coworkers (2010) (See [Table 8](#pone.0148052.t008){ref-type="table"})\[[@pone.0148052.ref063]--[@pone.0148052.ref067]\]. Vaginal *E*. *coli* carriage rates in Asia, Europe, North and South America appear lower. Different study populations, sampling and detection techniques might account for these differences.

10.1371/journal.pone.0148052.t008

###### Studies reporting (recto)vaginal *E*. *coli* carriage rates.

![](pone.0148052.t008){#pone.0148052.t008g}

  Country                                                                      Year   n      Population         \% E. coli                                                          Sample   Detection   Reference
  ---------------------------------------------------------------------------- ------ ------ ------------------ ------------------------------------------------------------------- -------- ----------- ----------------------------
  ***Africa* (pooled prevalence 36.0% (2846/7912); range 9.1--46.5%)**                                                                                                                                   
  Burkina Faso                                                                 2010   156    HIV+               28.4                                                                V        C           \[[@pone.0148052.ref067]\]
  Burkina Faso                                                                 2012   2000   S                  16.7                                                                V        C           \[[@pone.0148052.ref063]\]
  Kenya                                                                        2011   44     HIV+, HIV-, HESN   40.1                                                                V        cpn60       \[[@pone.0148052.ref065]\]
  Nigeria                                                                      1981   187    L                  9.1                                                                 C        C           \[[@pone.0148052.ref064]\]
  SA                                                                           2012   1347   P, HIV+            42.3                                                                V        C           \[[@pone.0148052.ref066]\]
  SA                                                                           2012   3752   P, HIV-            46.5                                                                V        C           \[[@pone.0148052.ref066]\]
  ***Asia* (pooled prevalence 5.3% (163/3072); range 0--25.8%)**                                                                                                                                         
  Iraq                                                                         2011   90     S, NP              16.2                                                                V        C           \[[@pone.0148052.ref068]\]
  Iraq                                                                         2011   20     S, P               25.8                                                                V        C           \[[@pone.0148052.ref068]\]
  Iran                                                                         2014   85     S, P               18.0                                                                V        C           \[[@pone.0148052.ref069]\]
  Japan                                                                        2002   2575   NP, P              3.4                                                                 V        C           \[[@pone.0148052.ref070]\]
  Pakistan                                                                     2012   100    HC                 28                                                                  V        C           \[[@pone.0148052.ref071]\]
  Pakistan                                                                     2012   100    H                  6                                                                   V        C           \[[@pone.0148052.ref071]\]
  Turkey                                                                       2007   34     IUD                14.7                                                                V        C           \[[@pone.0148052.ref072]\]
  Turkey                                                                       2007   34     HC                 2.9                                                                 V        C           \[[@pone.0148052.ref072]\]
  Turkey                                                                       2007   34     H                  0.0                                                                 V        C           \[[@pone.0148052.ref072]\]
  ***Europe* (pooled prevalence 13.4% (670/4980); range 3.1--51.2%)**                                                                                                                                    
  Croatia                                                                      2011   114    IUD                25.5                                                                V        C           \[[@pone.0148052.ref073]\]
  Croatia                                                                      2011   122    H                  8.2                                                                 V        C           \[[@pone.0148052.ref073]\]
  Denmark                                                                      2014   668    P                  11.7                                                                V        C           \[[@pone.0148052.ref074]\]
  Germany                                                                      2007   166    H                  16.3, 51.2, 25.9[^\*^](#t008fn002){ref-type="table-fn"}             V        C           \[[@pone.0148052.ref075]\]
  Greece                                                                       2008   1632   S                  3.1                                                                 V        C           \[[@pone.0148052.ref076]\]
  Lithuania                                                                    2012   970    P                  19.9                                                                V, R     C           \[[@pone.0148052.ref077]\]
  Spain                                                                        2002   623    P                  27.0                                                                V        C           \[[@pone.0148052.ref078]\]
  Spain                                                                        2011   321    P                  15                                                                  E, V     C           \[[@pone.0148052.ref079]\]
  Spain                                                                        2011   327    NP                 12                                                                  E, V     C           \[[@pone.0148052.ref079]\]
  Sweden                                                                       2008   37     H                  5.4                                                                 V        C           \[[@pone.0148052.ref080]\]
  ***North America* (pooled prevalence 12.7% (430/3373); range 0--29.5%)**                                                                                                                               
  Canada                                                                       1983   495    H                  12.3                                                                V        C           \[[@pone.0148052.ref081]\]
  US                                                                           1997   2646   P                  13.0                                                                V        C           \[[@pone.0148052.ref006]\]
  US                                                                           2001   44     H                  18.2, 9.1, 29.5, 6.8, 6.8 [^\#^](#t008fn003){ref-type="table-fn"}   V        C           \[[@pone.0148052.ref082]\]
  US                                                                           2005   20     H                  0                                                                   V        16S         \[[@pone.0148052.ref083]\]
  US                                                                           2012   70     P                  10                                                                  V        C           \[[@pone.0148052.ref084]\]
  US                                                                           2012   35     NP                 23                                                                  V        C           \[[@pone.0148052.ref084]\]
  US                                                                           2013   47     P                  2.1, 2.2, 5.6, 8.3[^£^](#t008fn004){ref-type="table-fn"}            V        C           \[[@pone.0148052.ref085]\]
  US                                                                           2013   16     NP                 6.3, 0, 12.5, 20                                                    V        C           \[[@pone.0148052.ref085]\]
  ***South America* (pooled prevalence 19.7% (135/684); range 14.3--23.0%)**                                                                                                                             
  Argentina                                                                    2013   259    P                  14.3                                                                V        C           \[[@pone.0148052.ref086]\]
  Chile                                                                        2009   425    S                  23.0                                                                V        C           \[[@pone.0148052.ref087]\]

The electronic bibliographic database PubMed was searched for articles using the search terms '(Escherichia) AND (coli) AND (vaginal)' with no date or language restriction. Studies were included if the number of vaginal *E*. *coli* carriers and the total number of individuals tested were reported; studies were excluded if women were not of childbearing age. 16S, deep sequencing of the 16S rRNA gene; cpn60, deep sequencing of the cpn60 gene; C, conventional culturing and identification; E, endocervial swab; FSW, female sex workers; H, healthy women; HC, women using hormonal contraception; HESN, HIV exposed seronegative women; IUD, women using an intrauterine device as contraception; L, women in labor; NP, non-pregnant women; P, pregnant women; Q, qPCR; R, rectal swab; S, women with vaginal symptoms or clinical diagnosis of infection; V, vaginal swab

^\*^pre, mid, post cycle, respectively

\# visit 1at 1 month before visit 2 and 19--24 days after cycle, 1--2 days before intercourse, 8-12h after intercourse, 3--4 days after intercourse, 5--6 days after intercourse

£ \<14weeks, between 14--28 weeks, \>28weeks, postpartum.

Compared to the reference group in Kenya, pregnant women had a lower prevalence of vaginal *E*. *coli* carriage; compared to the reference group in SA, adolescent women had a lower prevalence of *E*. *coli* carriage. The FSW study group in Kigali had a very high prevalence of *E*. *coli* carriage, i.e. 70%, and will be discussed below (risk factors).

To our knowledge, this is the first study to determine simultaneously the vaginal GBS and *E*. *coli* carriage rates in SSA populations using qPCR, known to be more sensitive than culture-based techniques. Moreover, vaginal carriage rates of GBS in Kenya and Rwanda and *E*. *coli* in Rwanda have not yet been described.

Risk factors for vaginal *E*. *coli* and GBS carriage {#sec024}
-----------------------------------------------------

The presence of vaginal *C*. *albicans*, recent vaginal intercourse, working as a FSW, an intermediate vaginal microbiome, BV, washing the vagina and cervical ectopy were independent risk factors for vaginal GBS or *E*. *coli* colonization.

Women carrying *C*. *albicans* were 3.6 times more likely also to carry GBS. Three US based studies have shown this same significantly positive association between GBS and *Candida* or yeast \[[@pone.0148052.ref040], [@pone.0148052.ref088], [@pone.0148052.ref089]\].

Intravaginal practices, like e.g. cleaning inside the vagina beyond the introitus or insertion of substances into the vagina to dry or tighten the vagina, are common in Africa and are associated with adverse outcomes including increased risk for BV and for sexually transmitted infections \[[@pone.0148052.ref090]\]. Our model showed that washing inside the vagina was an independent risk factor for vaginal GBS carriage: women were twice as likely to be colonized with GBS compared to women not washing inside the vagina. A study by van de Wijgert and coworkers \[[@pone.0148052.ref091]\] showed that women using substances other than plain water to finger-clean or wipe inside the vagina had a GBS prevalence of 26.3% (n = 99), whereas women not engaging in these practices had a GBS prevalence of 14.7% (n = 70). However, their findings did not reach significance, most probably because of the smaller sample size (169 women compared to 424 women in our study).

Women who had recent vaginal sex (the morning or evening before the study visit) were more than twice as likely to carry GBS vaginally than women who did not. Accordingly, a positive PSA test was also significantly correlated with GBS carriage. GBS is generally not considered an STI, and the influence of sexual behavior on vaginal GBS carriage or acquisition is a matter of debate \[[@pone.0148052.ref092]--[@pone.0148052.ref094]\]. Based on published literature and our own data, we hypothesize that sexual activity might lead to a brief temporal GBS colonization of the vagina. This hypothesis is strengthened by a recent longitudinal deep-sequencing study of the vaginal microbiome, where 25 women were sampled on a daily basis over a 10 week period, revealing an average of 0.39 GBS episodes per week and an average GBS episode of 2.8 days ([Fig 1](#pone.0148052.g001){ref-type="fig"} and additional file 4 in \[[@pone.0148052.ref095]\]), contrasting with earlier studies---where sampling occurred every 3 weeks---that report average GBS episodes of 13.7 weeks \[[@pone.0148052.ref096]\]. The brief colonization might explain why we and other authors find parameters such as 'age of first sexual intercourse' not to be associated with GBS carriage (they do not cover the recent aspect), while parameters such as 'high frequency of intercourse during last month' (as a consequence, a higher chance of also having had recent intercourse) do correlate. Taken together, GBS should be considered as a potentially pathogenic micro-organism that can be sexually transmitted and whose vaginal presence can be enhanced by sexual activity.

Cervical ectopy was an independent risk factor for vaginal *E*. *coli* carriage, 21.9% of women without cervical ectopy were *E*. *coli* carriers as opposed to 35.2% of women with cervical ectopy. Cervical ectopy has been associated with CT \[[@pone.0148052.ref097]\], HPV \[[@pone.0148052.ref098]\] and an increased susceptibility to HIV infection \[[@pone.0148052.ref099]\]. Although we could not determine the cause-effect relation of this association, it seems biologically plausible that a niche is created by the glandular columnar epithelium of women with cervical ectopy that somehow---directly or indirectly---favors the colonization by *E*. *coli*. Some studies have e.g. related cervical ectopy with a reduced cell-mediated or changed humoral immunity \[[@pone.0148052.ref021], [@pone.0148052.ref100]\].

Working as a FSW was an independent risk factor for vaginal *E*. *coli* carriage. We could not explain this by any of the sexual behavioural or other parameters presented in [Table 4](#pone.0148052.t004){ref-type="table"}. In our study, none of the participants, including the female sex workers, reported having had anal intercourse during the last 3 months. These percentages probably are underestimates, since stigma associated with anal intercourse often leads to reduced reporting \[[@pone.0148052.ref101]\]. Furthermore, Ghanem and coworkers \[[@pone.0148052.ref102]\] showed that regarding anal intercourse, significantly more women reported to engage in these practices when asked by means of computer assisted self interviews compared to face-to-face interviews, which was used in our study. It is not unlikely that FSW engage more in anal intercourse, compared to the general population, and that in our FSW population, vaginal contamination with *E*. *coli* is higher by transfer of (peri)anal bacteria during anal/vaginal intercourse. Other studies from East-Africa report anal intercourse prevalences in FSW of up to 40.8% \[[@pone.0148052.ref103]\]. Interestingly, anal intercourse during pregnancy has been reported as a significant risk factor for neonatal *E*. *coli* colonization \[[@pone.0148052.ref077]\].

Besides above-mentioned risk factors for GBS or *E*. *coli* carriage, we show for the first time that colonization with GBS and *E*. *coli*, the leading causes of EOS, are positively associated.

Abovementioned risk factors can be translated and implemented into strategies that aim to reduce the maternal carriage of GBS and *E*. *coli*. First, behavioral change by advocating abstinence from sexual intercourse and vaginal washing during late pregnancy, e.g. via counseling in family planning facilities, could help to reduce the risk of maternal GBS and *E*. *coli* colonization in resource-poor settings. Second, the extension of GBS screening with screening for *C*. *albicans* and *E*. *coli*--risk factors for vaginal GBS carriage--should be further investigated. Furthermore, the screening for *E*. *coli* itself also merits further investigation because of its role as a major EOS causative agent for which currently no prevention measures are taken, nor in low-income, nor in high-income countries \[[@pone.0148052.ref104]\]. In this context, the presence of cervical ectopy--a risk factor for vaginal *E*. *coli* carriage--should be further investigated.

GBS serotype distribution {#sec025}
-------------------------

As IAP is not effective against LOS and culture-based screening and administration of costly intravenous antibiotics might not be feasible in most low-income countries, an alternative and long-term solution lies in the development of effective GBS vaccines, that however would not cover for other micro-organisms causing EOS. As most GBS vaccines under development aim at eliciting protective antibodies against capsular polysaccharides, the principal difficulty in developing globally effective GBS vaccines is the existence of several serotypes with different geographical distributions. In our study, the most prevalent GBS serotypes were Ia (27.3%), V (27.3%) and III (22.7%) in Kenya; Ia (34.5%), V (31.0%), and IV (13.8%) in SA; and Ia (83.3%) and II (16.7%) in Rwanda. Only few other studies have documented vaginal GBS serotype distribution in Africa and these are largely in line with our findings ([Table 4](#pone.0148052.t004){ref-type="table"} and [Fig 1](#pone.0148052.g001){ref-type="fig"}).

Interestingly, compared to the low prevalences in Europe and the US, we found relatively high prevalences of serotypes IV, VI, VII--shown for the first time in sub-Saharan Africa---and VIII in the Kenyan and South African population (VI, 13.6%; VII, 4.5%; VIII 4.5% in Kenya, and IV, 13.8%; VI, 6.9%; VIII, 3.4% in SA) ([Table 4](#pone.0148052.t004){ref-type="table"}). In contrast, we did not detect any serotype Ib, which has, according to a recent meta-analysis, a prevalence of 8.1% in the US and 12.4% in Europe \[[@pone.0148052.ref038]\].

Differences in serotype distribution between our study and other studies ([Table 4](#pone.0148052.t004){ref-type="table"}) might be explained by differences in study populations, most studies listed in [Table 4](#pone.0148052.t004){ref-type="table"} typed strains isolated from pregnant women whereas most of our GBS strains were isolated from non-pregnant women. Methodological differences might also contribute. Many GBS capsular polysaccharide typing methods have been described, with the most commonly used method being a serological test, used by all studies listed in [Table 4](#pone.0148052.t004){ref-type="table"}, except our study. We used a molecular capsular typing method, developed and applied by European (reference) laboratories \[[@pone.0148052.ref105], [@pone.0148052.ref106]\]. Brigtsen and coworkers (2015) compared capsular typing of 426 GBS strains by a conventional latex agglutination test with PCR, and found that a substantial proportion of the strains were non-typeable by serotyping, but typeable by genotyping, and that an agreement between serotyping and genotyping was shown in 71.1% (of the isolates that were typeable by both methods) \[[@pone.0148052.ref107]\]. Moreover, we used a molecular technique directly on DNA extracts from vaginal swabs (and not on DNA extracts from isolates), which could lead to the detection of certain serotypes that would not have been isolated by culture.

Currently, there are two candidate vaccines in phase II clinical trials, i.e. a trivalent vaccine targeting serotypes Ia, Ib, and III, and a conjugate vaccine targeting serotype III ([www.clinicaltrials.gov](http://www.clinicaltrials.gov/)). In theory, the first vaccine could cover for 50.0%, 83.3% and 44.8% of vaginal GBS cases in our Mombasa, Kigali and Johannesburg population, respectively, but only a minority of women would be protected by the conjugate vaccine (22.7%, 0% and 10.3%, respectively).

GBS, *E*. *coli* and the vaginal microbiome {#sec026}
-------------------------------------------

Our results show that vaginal GBS and *E*. *coli* carriage were significantly associated with disturbances of the vaginal microbiome: compared to women with a normal vaginal microbiome, women with an intermediate vaginal microbiome were 2.61 times more likely to carry *E*. *coli*, whereas women with BV were 2.33 less likely to carry GBS. The latter finding is in accordance a study of Hillier and coworkers \[[@pone.0148052.ref108]\], reporting a significant negative association between GBS carriage and BV by Nugent scoring, studying 7,918 pregnant women. Two other studies did not confirm these findings \[[@pone.0148052.ref094], [@pone.0148052.ref109]\]. In depth analysis of abovementioned interdependencies of GBS, *E*. *coli*, *C*. *albicans*, BV and the vaginal microbiome will be published elsewhere.

Our study was limited by the fact that we used vaginal sampling instead of rectovaginal sampling for the detection of GBS (as recommended by the CDC), which has been shown to have higher recovery rates for GBS. Furthermore, we did not use a selective broth enrichment prior to PCR, as recommended by the CDC. In our study, pregnant women were up to 14 weeks of gestation, and were not sampled at 35--37 weeks' gestation as recommended by the CDC, which could have biased our results. Our study was further limited by the rather small sample size of our Rwanda study population.

In conclusion, vaginal GBS carriage rate and serotype distribution were similar to high-income countries, except for the higher prevalence of serotypes VI, VII and VIII. *E*. *coli* carriage rate was higher compared to high-income countries. We identified risk factors for GBS or *E*. *coli* carriage, ie. recent sexual intercourse, vaginal washing, *C*. *albicans* colonization and presence of cervical ectopy, that can be implemented in strategies to reduce maternal colonization. Immunoprophylaxis with current phase II candidate GBS vaccines would not protect the majority of women against vaginal GBS carriage in our study population. The most important causative agents of EOS, GBS and *E*. *coli*, both associated with disturbances of the vaginal microbiome, are positively associated.
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